Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 6

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 6
---
 Officer

The date of the Circular and Proxy Statement is , 2025 and, together with the enclosed form
of proxy card, is first being mailed to Shareholders on or about , 2025.

Neither the SEC, nor any state securities commission has approved or disapproved of the transactions described in this Circular and Proxy Statement, including the Arrangement; passed upon the merits or fairness of the transactions described in this Circular and Proxy Statement, including the Arrangement; or determined if the information contained in this Circular and Proxy Statement is accurate or adequate. Any representation to the contrary is a criminal offense.

4

REPARE THERAPEUTICS INC. 7171 Frederick-Banting, Building 2, Suite 270 St-Laurent,Québec, Canada H4S 1Z9 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS AND INFORMATION CIRCULAR AND PROXY STATEMENT To the Shareholders of Repare Therapeutics Inc.: Notice is hereby given that a special meeting (“ Special Meeting”) of the holders of Repare Therapeutics Inc., a company existing under the laws of Québec (the “ Company”), common shares (the “ Common Shares,” and the holders of such Common Shares, the “ Shareholders”) will be held on January 16, 2026 at 10:00 a.m. (Montreal time) via live webcast for the following purposes:

| (1) | pursuant to an order from the Superior Court of Québec (Commercial Division), dated as of                                                                                                                                 
 December   , 2025 (the “Interim Order”), to consider and, if thought advisable, to pass, with or without variation, a special resolution (the “Arrangement Resolution”), the full text of which is                        
 set forth in Annex D to the accompanying proxy statement and management information circular (the “Circular and Proxy Statement”), approving a plan of arrangement (the “Plan of Arrangement”) under Chapter XVI          
 – Division II of the Business Corporations Act (Québec) (the “QBCA”) involving the Company, XenoTherapeutics, Inc., a company existing under the Laws of Massachusetts (the “Parent”), Xeno                               
 Acquisition Corp., a company existing under the laws of Delaware (the “Purchaser”) and XOMA Royalty Corporation, a company existing under the laws of Nevada (“XRC”) pursuant to an arrangement agreement dated           
 November 14, 2025 (the “Agreement”), whereby the Purchaser will, among other things, acquire all